Kissei Pharmaceutical Co., Ltd.

TSE:4547 Stock Report

Market Cap: JP¥163.6b

Kissei Pharmaceutical Valuation

Is 4547 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4547 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4547 (¥3700) is trading below our estimate of fair value (¥6272)

Significantly Below Fair Value: 4547 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4547?

Other financial metrics that can be useful for relative valuation.

4547 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.6x
Enterprise Value/EBITDA13.6x
PEG Ratio-2x

Price to Earnings Ratio vs Peers

How does 4547's PE Ratio compare to its peers?

The above table shows the PE ratio for 4547 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average19.6x
4521 Kaken Pharmaceutical
20.1x-44.6%JP¥146.2b
4553 Towa Pharmaceutical
9.2x-4.2%JP¥155.5b
4534 Mochida Pharmaceutical
28xn/aJP¥123.4b
4551 Torii Pharmaceutical
21x-0.9%JP¥110.2b
4547 Kissei Pharmaceutical
13.6x-6.8%JP¥163.6b

Price-To-Earnings vs Peers: 4547 is good value based on its Price-To-Earnings Ratio (13.6x) compared to the peer average (19.6x).

Price to Earnings Ratio vs Industry

How does 4547's PE Ratio compare vs other companies in the JP Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.9%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.9%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: 4547 is good value based on its Price-To-Earnings Ratio (13.6x) compared to the JP Pharmaceuticals industry average (15.9x).

Price to Earnings Ratio vs Fair Ratio

What is 4547's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4547 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.6x
Fair PE Ratio13.2x

Price-To-Earnings vs Fair Ratio: 4547 is expensive based on its Price-To-Earnings Ratio (13.6x) compared to the estimated Fair Price-To-Earnings Ratio (13.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4547 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥3,700.00
JP¥3,950.00
+6.8%
8.5%JP¥4,400.00JP¥3,600.00n/a3
Sep ’25JP¥3,460.00
JP¥3,883.33
+12.2%
6.3%JP¥4,200.00JP¥3,600.00n/a3
Aug ’25JP¥3,490.00
JP¥3,710.00
+6.3%
9.8%JP¥4,200.00JP¥3,330.00n/a3
Jul ’25JP¥3,230.00
JP¥3,643.33
+12.8%
10.8%JP¥4,200.00JP¥3,330.00n/a3
Jun ’25JP¥3,145.00
JP¥3,643.33
+15.8%
10.8%JP¥4,200.00JP¥3,330.00n/a3
May ’25JP¥3,595.00
JP¥3,833.33
+6.6%
14.2%JP¥4,600.00JP¥3,400.00n/a3
Apr ’25JP¥3,465.00
JP¥3,833.33
+10.6%
14.2%JP¥4,600.00JP¥3,400.00n/a3
Mar ’25JP¥3,415.00
JP¥3,716.67
+8.8%
17.0%JP¥4,600.00JP¥3,150.00n/a3
Feb ’25JP¥3,155.00
JP¥3,716.67
+17.8%
17.0%JP¥4,600.00JP¥3,150.00n/a3
Jan ’25JP¥3,090.00
JP¥3,650.00
+18.1%
14.8%JP¥4,400.00JP¥3,150.00n/a3
Oct ’24JP¥3,390.00
JP¥3,350.00
-1.2%
1.5%JP¥3,400.00JP¥3,300.00JP¥3,610.002
Sep ’24JP¥3,450.00
JP¥3,350.00
-2.9%
1.5%JP¥3,400.00JP¥3,300.00JP¥3,460.002
Aug ’24JP¥3,490.00
JP¥3,175.00
-9.0%
3.9%JP¥3,300.00JP¥3,050.00JP¥3,490.002
Jul ’24JP¥2,878.00
JP¥3,175.00
+10.3%
3.9%JP¥3,300.00JP¥3,050.00JP¥3,230.002
Jun ’24JP¥2,843.00
JP¥3,175.00
+11.7%
3.9%JP¥3,300.00JP¥3,050.00JP¥3,145.002
May ’24JP¥2,754.00
JP¥3,075.00
+11.7%
7.3%JP¥3,300.00JP¥2,850.00JP¥3,595.002
Apr ’24JP¥2,641.00
JP¥3,075.00
+16.4%
7.3%JP¥3,300.00JP¥2,850.00JP¥3,465.002
Mar ’24JP¥2,435.00
JP¥3,000.00
+23.2%
10.0%JP¥3,300.00JP¥2,700.00JP¥3,415.002
Feb ’24JP¥2,630.00
JP¥3,000.00
+14.1%
10.0%JP¥3,300.00JP¥2,700.00JP¥3,155.002
Jan ’24JP¥2,580.00
JP¥3,000.00
+16.3%
10.0%JP¥3,300.00JP¥2,700.00JP¥3,090.002
Dec ’23JP¥2,521.00
JP¥2,955.00
+17.2%
11.7%JP¥3,300.00JP¥2,610.00JP¥3,125.002
Nov ’23JP¥2,621.00
JP¥2,955.00
+12.7%
11.7%JP¥3,300.00JP¥2,610.00JP¥3,215.002
Oct ’23JP¥2,573.00
JP¥2,955.00
+14.8%
11.7%JP¥3,300.00JP¥2,610.00JP¥3,390.002

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y